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WE measured sIL-2R, TNF- and slCAM-1 in the Detection of soluble interleukin-2
sera and middle ear effusions (MEEs) of patients
with otitis media with effusion (OME). Although receptor and soluble intercellular
there was no signmcant difference between the adhesion molecule-1 in the effusion sIL-2R levels of the serous and mucoid MEEs, they
were significantly higher than serum sIL-2R of otitis media with effusion
levels of OME patients and healthy controls. TNF-
levels of the mucoid MEEs were significantly
higher than those of the serous type. However,
TNF- was rarely detected in the sera of OME T. Ganbo,1"cA K.-I. Hisamatsu, H. Inoue,2
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niflcant differences between the serous and
mucoid MEEs with respect to their sICAM-1 levels,
which were also higher than serum slCAM-1 1Department of Otolaryngology, Yamanashi
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findings suggested that IL-2, TNF- and ICAM-1 of Plastic t Reconstructive Surgery, St Marianna could be significantly involved in the pathogen-
esis ofOME through the cytokine network. University School of Medicine, Kawasaki, Japan
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Introduction submucosa of the middle ears. 18’19 Cytokines
form a network together with inflammatory cells
Interleukin-2 (IL-2) is one of the most well and adhesion molecules, and play important
characterized cytokines. It stimulates the pro- roles in the inflammatory disorders. It is neces-
liferation of activated T-lymphocytes,1’2 and binds salT to investigate the effects of cytokines and
to the IL-2 receptor (IL-2R) which is composed adhesion molecules on the pathogenesis of OME.
of three distinct subunits, namely a, [3 and T. However, there have been few reports about slL-
chains.3-5 In patients with rheumatoid arthritis,
6 2R and slCAM-1 in cases with OME. Therefore,
adult T cell leukaemia,
7 Kawasaki disease
8 and we studied slL-2R, TNF-a and slCAM-1 in the
bronchial asthma,9 the serum levels of soluble IL- middle ear effusion and the sera of patients with
2R (slL-2R), which is the released extracellular OME.
domain of the a-chain of IL-2R, are elevated.
Moreover, activated T-lymphocytes are reported
not only to elaborate interferon-gamma (INF-T) Materials and Methods
and to cause macrophages to produce turnout
necrosis factor-alpha (TNF-a),
11 but also to reg- Subjects: We collected middle ear effusions
ulate the expression of intercellular adhesion (MEEs) using Juhn Tyro-Taps (Xomed-Treace,
molecule-1 (ICAM-1) on the endothelium indir- Jacksonville, FL, USA) from 31 patients with
ectly through such media as TNF-a and INF-T, OME (17 males and 14 females, ranging in age
resulting in the recruitment of inflammatory from 3 to 79 years with a mean of 22.9 years)
cells.
2 ICAM-1 belongs to the immunoglobulin when they had undergone myringotomy. The
supergene family
13 and acts a ligand for leuko- MEEs were classified into two groups, the
cyte function-associated antigen-1 (LFA-1)
14 and serous and the mucoid types. While 16 patients
integrin corresponding to the [32 group (Mac- (nine males and seven females with a mean age
1).15 It plays important roles in intercellular inter- of 22.9 years, ranging from 4 to 76 years)
action when leukocytes adhere and transmigrate belonged to the serous type, 15 others (eight
to a focus. Thus, soluble ICAM-1 (slCAM-1), a males and seven females with a mean age of
soluble form of ICAM-1, is detected in the focus 23.0 years, ranging from 3 to 79 years) belonged
because of the shedding of ICAM-1 as well as the to the mucoid type. Serum samples were also
expression of lCAM-1 on the cell surface induced obtained from all 31 patients with OME, and
by TNF-a and INF-T.16’7 from ten healthy volunteers who served as con-
In otitis media with effusion (OME), pre- trols, MEEs and sera were collected with the
dominant neutrophils with lymphocytes and mac- informed consent of the patients and/or their
rophages are seen in the effusion and the families.
350 Mediators of Inflammation Vol 4. 1995 (C) 1995 Rapid Science PublisherssIL-2R and sICAM-1 in OME
Preparation ofMEEs and sera: One to 3 volumes
of dithiothreitol
2 (Sputolysin(R); Behring Diag-
nostics, La Jolla, CA, USA) were added to the
MEEs and mixed with a vortex mixer to dissolve
in phosphate-buffered saline (PBS). Finally, the
sample was diluted to the concentration of 2 to
10 volumes of the MEE with dithiothreitol and
PBS. These samples were centrifuged at 1500 x g
for 10 min, and the supernatants were collected
and stored at-80C until they were assayed. The
sera were also stored in the same way.
The assays for sIL-2R, TNFz and sICAM-I: The
concentrations of sIL-2R, TNF- and sICAM-1
were measured using commercially available
enzyme-linked immunosorbent assays (ELISA).
The assays of slL-2R, TNF<z and slCAM-1 were
performed in duplicate with cell-free interleukin-
2 receptor bead assay kit (T cell Diagnostic Co.,
MA, USA), human TNF-z immunoassay kit
(Research and Diagnostics Systems, MN, USA)
and human ICAM-1 ELISA kit (Serotec, Oxford,
England), respectively. The concentrations of slL-
2R, TNF-z and slCAM-1 in the test samples were
determined from the calibration curve.
For the measurement of slL-2R, TNF-z and
slCAM-1 in the MEE, the effect of the MEE itself
on these assays was preliminarily tested but no
significant effect was found. Briefly, three kinds
of stock solutions obtained from surplus MEEs
were prepared for the test. An equal volume of
each of standard slL-2R, TNF<z and slCAM-1 was
added to each stock solution and the actual
increase in slL-2R, TNF<z and slCAM-1 concentra-
tions was compared with the calculated value.
Statistical analysis: The statistical significance of
the difference between the recorded values was
determined at p < 0.01 by Student’s t-test.
Results
The levels of sIL-2R in the MEEs and sera are
illustrated in Fig. 1. The mean level of sIL-2R in
the mucoid MEEs was 15000U/ml, while the
mean level in the serous MEEs was 9500 U/ml.
There was no significant difference between the
slL-2R levels of the two types of MEEs. However,
the slL-2R levels in both types were significantly
higher than those of the sera of OME patients,
which was 326U/ml on the average. Moreover,
there was no significant difference between the
sera of OME patients and those of the healthy
controls (310 U/ml).
The levels of TNF<z in the MEEs and sera are
illustrated in Fig. 2. The mean level of TNF-z in












Serum Serum Serous Mucoid
control OME MEE MEE
FIG. 1. The slL-2R levels in the serous (n=8) and mucoid MEEs
(n 11) of OME patients are shown along with serum levels of
slL-2R in healthy control volunteers (n 10) and OME patients
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FIG. 2. The TNF- levels in the serous (n 11) and mucoid MEEs
(n=8) of OME patients are shown along with serum levels of
TNF- in healthy control volunteers (n 10) and OME patients
(n 19). Each bar represents mean and S.D. **p < 0.01.
mean level in the serous MEEs was 66pg/ml.
There was a significant difference between the
TNF-z levels of the two types of MEEs. TNF-z
was detected in the sera of five out of 19 cases
and their mean level was 7.8 pg/ml. The TNF-z
levels of the two types of MEEs were significantly
different from those of the sera of the detected
cases. The mean of the total serum levels of
TNF-0t including 14 undetected cases was 2.1 pg/
ml, which was as high as that of the healthy con-
trois (2.1 pg/ml).
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FIG. 3. The slCAM-1 levels in the serous (n=9) and mucoid
MEEs (n 7) of OME patients are shown along with serum levels
of slCAM-1 in healthy control volunteers (n= 10) and OME
patients (n 16). Each bar represents mean and S.D. **p < 0.01.
The levels of slCAM-1 in the MEEs and sera
are illustrated in Fig. 3. The mean level of sICAM-
1 in the mucoid MEEs was 1440 ng/ml, whereas
the mean level in the serous MEEs was 430 ng/
ml. Thus, a significant difference was observed
between slCAM-1 levels of the two types of
MEEs. Furthermore, the levels of slCAM-1 in the
two types of MEEs were significantly different
from those of the sera of the OME patients
because the mean serum level was 180ng/ml.
However, there was no significant difference
between the sera of the OME patients and those
of the healthy controls (180 ng/ml).
Discussion
The slL-2R levels in the serous and mucoid
types of MEEs were high, their mean values
being 9500 U/ml and 15 000 U/ml, respectively.
These values were extremely high as compared
with the sIL-2R levels of bronchoalveolar lavage
fluid (BALF) of asthma (42U/ml) and miliary
tuberculosis (1320U/ml),9 nasal secretion of
nasal allergy (1510 U/ml)2 and synovial effusion
of rheumatoid arthritis (1170 U/ml).6 Even in the
severe cases of acute asthma,
22 extensive pul-
monary tuberculosis2 and acute-phase Kawasaki
disease,s it was reported that the mean values of
serum slL-2R levels were about 570 U/ml, 2700 U/
ml and 3700 U/ml, respectively. However, slL-2R
level of acute adult T cell leukaemia which was
beyond 10000 U/ml in serum,
7 was as high as
that of MEE. In our study, the mean level of slL-
2R in the sera of OME patients was 326 U/ml,
which was the same as that of the healthy con-
trois (310U/ml). These data suggest that the
expression of IL-2R on activated T lymphocytes
and the binding of IL-2 to its receptor might be
concerned with local pathogenesis of OME in the
middle ear. Yellon et a/.24 also reported that IL-2
was detected in the MEEs of 54% of OME
patients. However, there is a possibility that IL-2
might be biologically a little unstable or techni-
cally difficult to detect as compared with slL-2R,
because slL-2R was detectable in all our cases.
There are a few reports which claim that TNF-
cz was detected in the MEEs of OME,
24-26
although its values were expressed with the unit
of pg/mg of total protein. Particularly, the
mucoid type effusion is too viscous to dissolve in
PBS. In our methods, we used dithiothreitol and
liquefied the mucoid pellet to dissolve it in
PBS.
2 We expressed TNF<z levels in the effusion
with the unit of pg/ml and could compare TNF<z
values with those of other diseases. In the
BAIs27 and sputa
28 of patients with active
asthma, mean TNF-z levels were 578 pg/ml and
1783 pg/ml, respectively. In children with leukae-
mia, the mean level of TNF-cz in the sera was
63.6pg/ml while it was 21.5 pg/ml in the solid
tumours.29 We found that the mean TNF-z level
in the mucoid type effusions was similar to that
in BALFs of asthma patients.
Chihara et al. reported that slCAM-1 levels of
sputa and sera of asthma patients were 8.6 ng/ml
and 350ng/ml, respectively, and that the slCAM-1
level in the normal human sera was 200 ng/ml. It
means that the mean serum level of slCAM-1 in
asthma was 1.75 times higher than that in the
healthy control and that its sputum level could
be disregarded as it was too low as compared
with the serum level of control subjects. In our
study, slCAM-1 levels in the serous and mucoid
MEEs were 5.3 and 7.8 times higher than those
in the control sera. slCAM-1 levels in various
other diseases have also been reported. In
patients with rheumatoid arthritis, serum and
synovial fluid levels of slCAM-1 were 1.2 and 1.5
times higher than the serum levels of the normal
controls, respectively. Serum levels of sICAM-1 in
patients with nasal allergy32 and malignant dis-
16 eases with metastasis were 1.4 and 5.7 times
higher than those of the healthy controls, respec-
tively. These data indicate that slCAM-1 levels
detected in the MEEs of OME were very high
while the serum levels were the same as those of
the healthy controls. Himi et al. also reported
that slCAM-1 levels of MEEs were significantly
higher than those of the healthy control sera.
However, they could not make any distinction
between the various types of the MEEs because
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their sICAM-1 levels were expressed in ng/mg of
total protein, which was different from our unit
ng/ml. However, it is not surprising that sICAM-1,
a soluble component of ICAM-1, was highly
detectable in the MEEs. It is supposed that ICAM-
1 might play an important role in inflammatory
disorders of the middle ear. Our investigation
suggested that ICAM-1 might cause a difference
in the production and/or accumulation of MEE
because there was a significant difference
between the slCAM-1 levels of the serous and
mucoid MEEs. This supposition was highly
acceptable also for the fact that there was sig-
nifican difference between the TNF-0t levels of
the two types of MEEs and that TNF<z also acti-
vates endothelium, causing the expression of
adhesion molecules such as ICAM-1.12
The physiological significance of the shedding
of sIL-2R and sICAM-1 remains unknown.
However, we supposed that they might be
playing some role in inflammatory disorders.
There is a possibility that they could serve as
useful markers of inflammation, and may also
have inhibitory effects on the inflammatory
cascade of reactions, because slL-2R inhibits the
functional response elicited by IL-2,
6 and slCAM-1
prevents cell adherence to native ICAM-1.6-7 IL-
2 induces the proliferation of activated lympho-
cytes and ICAM-1 also facilitates adhesion and
transmigration of neutrophils.4 These inflamma-
tory cells invade the middle ear of OME patients.
In cases of serous types of OME, it was reported
that a larger number of neutrophils and lympho-
cytes were observed in the MEEs and that more
severe inflammatory signs were shown in the
submucosa, as compared with mucoid types.18’19
However, particularity in our study, slCAM-1
levels of mucoid MEEs were significantly higher
than those of serous MEEs. These morphological
findings of cellular infiltration, which might be
induced by ICAM-1, disagreed with slCAM-1
levels detected in the MEEs. Therefore, it is
necessary to investigate the more detailed roles
of slL-2R and slCAM-1 in the pathogenesis of
OME.
It has been reported that various chemical
mediators such as leukotrienes, prostaglandins5
and platelet activating factor were detectable in
the MEEs of OME. These chemical mediators are
responsible at least partly for the pathogenesis of
OME because they could induce hypersecretion
and inhibit mucociliary transport systems in the
middle ear, causing an accumulation of the effu-
sion.v’ However, these mediators could also be
secreted by inflammatory cells that infiltrated into
the focus. Furthermore, these inflammatory cells
are regulated by the cytokine network that con-
sists of cytokines and related factors. Our investi-
gation indicated the possibility that IL-2, TNF<z
and ICAM-1 could affect the pathogenesis of
OME through the inflammatory cells and the
chemical mediators derived from these cells.
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